3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
2
FED
1
Study Type
Interventional
2
Sponsor
Conditions
Neoplasms
2870
Carcinoma, Non-Small-Cell Lung
2420
Breast Neoplasms
2065
Colorectal Neoplasms
1239
Neoplasm Metastasis
1223
Prostatic Neoplasms
1076
Melanoma
972
Multiple Myeloma
960
Ovarian Neoplasms
899
Recurrence
849
Leukemia, Myeloid, Acute
807
Lung Neoplasms
756
Pancreatic Neoplasms
750
Lymphoma, Non-Hodgkin
726
Lymphoma
660
Stomach Neoplasms
622
Carcinoma, Hepatocellular
564
Carcinoma, Renal Cell
544
Squamous Cell Carcinoma of Head and Neck
525
Leukemia, Lymphocytic, Chronic, B-Cell
493
Lymphoma, Follicular
468
Head and Neck Neoplasms
449
Glioblastoma
435
Advanced Solid Tumors
430
Small Cell Lung Carcinoma
408
Triple Negative Breast Neoplasms
407
Lymphoma, Large B-Cell, Diffuse
398
Leukemia
394
Uterine Cervical Neoplasms
367
Advanced Solid Tumor
349
Interventions
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Lymphatic Abnormalities
×
Clear all
NCT05948943
2026-05-12
EPIK-L1
Novartis
Phase 2/3
Recruiting
232 enrolled
NCT06239480
2026-03-27
SELVA
Palvella Therapeutics, Inc.
Phase 3
Active not recruiting
51 enrolled